NYSE:CBM - Cambrex Stock Price, News, & Analysis

Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."

Cambrex Co. (NYSE:CBM) posted its earnings results on Thursday, November, 8th. The biotechnology company reported $0.49 EPS for the quarter, missing analysts' consensus estimates of $0.59 by $0.10. The biotechnology company earned $104.62 million during the quarter, compared to the consensus estimate of $122.04 million. Cambrex had a return on equity of 22.20% and a net margin of 22.67%. The company's revenue for the quarter was down 7.1% on a year-over-year basis. During the same period last year, the firm posted $0.55 EPS. View Cambrex's Earnings History.

Cambrex is scheduled to release their next quarterly earnings announcement on Thursday, February 14th 2019. View Earnings Estimates for Cambrex.

Cambrex issued an update on its FY 2018 earnings guidance on Thursday, November, 8th. The company provided EPS guidance of $2.95-3.09 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.79.

5 Wall Street analysts have issued 1-year target prices for Cambrex's stock. Their predictions range from $63.00 to $75.50. On average, they anticipate Cambrex's share price to reach $69.25 in the next year. This suggests a possible upside of 62.0% from the stock's current price. View Analyst Price Targets for Cambrex.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 1 hold rating, 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cambrex.

News coverage about CBM stock has trended negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cambrex earned a media sentiment score of -2.5 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the stock's share price in the near future.

Some companies that are related to Cambrex include Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), SAGE Therapeutics (SAGE), Amarin (AMRN), GALAPAGOS NV/S (GLPG), Alkermes (ALKS), United Therapeutics (UTHR), Catalent (CTLT), TESARO (TSRO), FibroGen (FGEN), Amneal Pharmaceuticals (AMRX), GW Pharmaceuticals PLC- (GWPH), Array Biopharma (ARRY), Taro Pharmaceutical Industries (TARO) and Horizon Pharma (HZNP).

Cambrex's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Copper Rock Capital Partners LLC (1.17%), Summit Creek Advisors LLC (0.68%), Confluence Investment Management LLC (0.28%), Scout Investments Inc. (0.27%), IMA Wealth Inc. (0.10%) and Louisiana State Employees Retirement System (0.04%). Company insiders that own Cambrex stock include Gregory Sargen, Ilan Kaufthal, Leon J Hendrix Jr, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Institutional Ownership Trends for Cambrex.

CBM stock was sold by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC, Louisiana State Employees Retirement System, Confluence Investment Management LLC, Scout Investments Inc., IMA Wealth Inc. and 6 Meridian. Company insiders that have sold Cambrex company stock in the last year include Gregory Sargen, Ilan Kaufthal, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Insider Buying and Selling for Cambrex.

CBM stock was acquired by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, Fox Run Management L.L.C. and State of Alaska Department of Revenue. View Insider Buying and Selling for Cambrex.

Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CBM stock can currently be purchased for approximately $42.75.

Cambrex has a market capitalization of $1.57 billion and generates $534.46 million in revenue each year. The biotechnology company earns $102.45 million in net income (profit) each year or $3.17 on an earnings per share basis. Cambrex employs 1,228 workers across the globe.

The official website for Cambrex is http://www.cambrex.com.

Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]